Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07812116Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Oct 2026
- Primary completion
- Jun 2028
01
Overview
Phase 2, randomised, double-blind trial of duvakitug in hidradenitis suppurativa (HS) (3 arms), sponsored by Sanofi. Primary endpoint: Hidradenitis Suppurativa Clinical Response 75 at 16 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
duvakitug
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07812116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07812116.